Spruce Biosciences (SPRB)
(Real Time Quote from BATS)
$0.47 USD
-0.01 (-1.88%)
Updated Aug 28, 2024 01:34 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Spruce Biosciences, Inc. [SPRB]
Reports for Purchase
Showing records 1 - 20 ( 24 total )
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Collaboration Announced in Depression; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Data Analyses Lend Hope to Tildacerfont; 1Q24 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CAHmelia-203 Trial Fails; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CAHmelia-204 Study Completes Enrollment; Data in 3Q24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Catalyst-Rich 2024 Sets Stage for Value Inflection; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Tildacerfont Data Catalysts Approaching; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Competitor Data Validate and Risk-Mitigate Tildacerfont; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Tildacerfont Continues Clinical Advance; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Tildacerfont Poster Upcoming; Clinical Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Tildacerfont Progress; 2022 Financial Results; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Tildacerfont Strategic Partnership Inked With Kaken; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Tildacerfont Clinical Readouts Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Data Catalysts Gradually Approaching; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Regulatory Affairs Function Bolstered; 1Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Still Considerably Undervalued; 2021 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Updates and 2022 Outlook Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Management Changes Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spruce Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Delays; Leadership Changes Announced; Lowering PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R